Cargando…
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance
DNA fragments released from cancer cells into the blood can be used to generate molecular profiles of tumors. Non-invasive 'liquid biopsies' can be used to monitor minimal residual disease and detect the emergence of drug resistance.
Autores principales: | Siravegna, Giulia, Bardelli, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281953/ https://www.ncbi.nlm.nih.gov/pubmed/25222559 http://dx.doi.org/10.1186/s13059-014-0449-4 |
Ejemplares similares
-
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
por: Siravegna, Giulia, et al.
Publicado: (2017) -
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
por: Crisafulli, Giovanni, et al.
Publicado: (2023) -
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
por: Leal, Alessandro, et al.
Publicado: (2020) -
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016) -
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours
por: Bertero, L., et al.
Publicado: (2019)